Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HWY0101 is an investigational small molecule drug candidate being developed by Kanion Pharmaceutical (Jiangsu Kanion Pharmaceutical) and Huawe Medicine for the treatment of sialorrhea (excessive drooling) in patients with neurological disorders, including severe chronic drooling associated with conditions such as cerebral palsy. Sialorrhea is characterized by the involuntary flow of saliva out of the mouth, which can lead to physical and psychosocial complications. HWY0101 is currently in Phase 1 clinical development in China, with the sponsors holding rights for further development in Europe and Japan. While the specific molecular target has not been publicly disclosed by the developers, therapies for this indication typically function by inhibiting muscarinic receptors in the salivary glands to reduce saliva production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HWY0101.